Versant Venture Capital VI, L.P.
10% owner at Monte Rosa Therapeutics; 10% owner at LENZ Therapeutics; 10% owner at Tempest Therapeutics.
- Rank
- 766th of 809
- Companies held
- 3
- Largest holding
- GLUE, 88.1% of total
- Latest SEC filing
- Sep 18, 2025
- Listed but not counted
- $20.4M
What the $57.2M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics GLUE Common Stock | Directly | 4,079,469 | $8.91 | $36.3M | 63.6% | Form 4, Oct 28, 2024 |
| Monte Rosa Therapeutics GLUE Common Stock | Indirectly (see filing footnote) | 1,573,453 | $8.91 | $14.0M | 24.5% | Form 4, Oct 29, 2024 |
| LENZ Therapeutics LENZ Common Stock | Directly | 1,183,543 | $3.34 | $4.0M | 6.9% | Form 4, Sep 18, 2025 |
| LENZ Therapeutics LENZ Common Stock | Indirectly (see filing footnote) | 856,157 | $3.34 | $2.9M | 5.0% | Form 4, Sep 18, 2025 |
| Tempest Therapeutics TPST Common Stock | Directly | 16,149 split-adjusted | $0.31 | $5K | 0.0% | Form 4, Aug 12, 2024 |
Share counts are the amounts Versant Venture Capital VI, L.P. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Versant Venture Capital VI, L.P.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics GLUE Common Stock | Through Versant Vantage I, L.P. Held by a company or fund the insider manages | 1,589,053 | $8.91 | $14.2M | — | Form 4, Oct 29, 2024 |
| LENZ Therapeutics LENZ Common Stock | Through Versant Venture Capital VII, L.P. Held by a company or fund the insider manages | 876,437 | $3.34 | $2.9M | — | Form 4, Sep 18, 2025 |
| LENZ Therapeutics LENZ Common Stock | Through Versant Vantage II, L.P. Held by a company or fund the insider manages | 842,162 | $3.34 | $2.8M | — | Form 4, Sep 18, 2025 |
| Monte Rosa Therapeutics GLUE Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 20,397 | $8.91 | $182K | — | Form 4, Oct 28, 2024 |
| Monte Rosa Therapeutics GLUE Common Stock | Indirectly (see filing footnote) Held by an investment fund or partnership | 17,595 | $8.91 | $157K | — | Form 4, Oct 28, 2024 |
| Tempest Therapeutics TPST Common Stock | Through Versant Vantage II, L.P. Held by a company or fund the insider manages | 162,973 split-adjusted | $0.31 | $50K | — | Form 4, Aug 8, 2024 |
| Monte Rosa Therapeutics GLUE Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 5,499 | $8.91 | $49K | — | Form 4, Oct 28, 2024 |
| Monte Rosa Therapeutics GLUE Common Stock | Indirectly (see filing footnote) Held by an investment fund or partnership | 5,454 | $8.91 | $49K | — | Form 4, Oct 28, 2024 |
| Tempest Therapeutics TPST Common Stock | Through Versant Venture Capital IV, L.P. Held by a company or fund the insider manages | 90,084 split-adjusted | $0.31 | $28K | — | Form 4, Aug 8, 2024 |
| Tempest Therapeutics TPST Common Stock | Through Versant Side Fund IV, L.P. Held by a company or fund the insider manages | 567 split-adjusted | $0.31 | $174 | — | Form 4, Aug 8, 2024 |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 763 | CPIF Sparti SAF, L.P. Director, Sonida Senior Living | $58.1M |
| 764 | Oaktree Acquisition Holdings III LS GP, Ltd. 10% owner, Oaktree Acquisition Corp. III Life Sciences | $57.8M |
| 765 | Petit Monts LLC 10% owner, American Drive Acquisition | $57.3M |
| 766 | Versant Venture Capital VI, L.P. 10% owner, Monte Rosa Therapeutics | $57.2M |
| 767 | AP IX College Holdings GP, LLC 10% owner, Taboola.com | $56.5M |
| 768 | College Parent Holdings GP, LLC 10% owner, Taboola.com | $56.2M |
| 769 | Pfizer INC 10% owner, ORIC Pharmaceuticals | $56.0M |
Other Monte Rosa Therapeutics insiders
All GLUE insiders- Markus Warmuth$5.2MPresident & CEO. #14051 overall
Questions
How much stock does Versant Venture Capital VI, L.P. own?
Versant Venture Capital VI, L.P. holds $57,185,073 in listed stock based on SEC filings and current prices, mostly Monte Rosa Therapeutics (GLUE). That ranks 766th on the Stock Rich List.
Is this Versant Venture Capital VI, L.P.'s net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.